Alembic Pharmaceuticals secures USFDA approval for new Paliperidone extended-release tablets
Alembic Pharmaceuticals Limited has achieved a major milestone in the pharmaceutical industry. On September 27, 2024, the company proudly announced that it received final approval ... Read More
Indoco Remedies secures FDA tentative approval for Canagliflozin Tablets
Indoco Remedies Ltd., a renowned player in the global pharmaceutical industry, has announced receiving tentative approval from the United States Food and Drug Administration (USFDA) ... Read More
Lupin obtains tentative FDA approval for generic Canagliflozin Tablets
Global pharmaceutical leader, Lupin Limited, announced its significant achievement of receiving tentative approval from the United States Food and Drug Administration (U.S. FDA) for its ... Read More
Janssen Covid‑19 vaccine gets conditional marketing authorization in EU
The European Commission has granted a conditional marketing authorization (CMA) for the single dose Janssen Covid‑19 vaccine developed by the Janssen Pharmaceutical Companies of Johnson ... Read More
ViiV Healthcare’s Cabenuva secures FDA approval for HIV treatment
ViiV Healthcare has received FDA approval for Cabenuva, a long-acting treatment regimen for HIV-1 infection in adult patients. This new therapy is poised to transform ... Read More
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy, a severe form of age-related macular degeneration ... Read More
EC strikes deal for supply of JNJ-78436735 Covid-19 vaccine candidate
Johnson & Johnson (J&J) said that the European Commission (EC) has approved an advance purchase agreement for securing 200 million doses of the JNJ-78436735 Covid-19 ... Read More
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients ... Read More
Janssen secures EC approval for daratumumab as new multiple myeloma therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson have achieved a significant milestone with the European Commission's approval of Darzalex (daratumumab) for use as an ... Read More
Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA ... Read More